@RaceOncology
I know we're getting Decitabine for free, but wouldn't it make more sense to delay the AML trial ~6 months, let any unexercised bonus options lapse, raise another $10m (at what I'll speculate would be far less dilution) and roll straight into Venetoclax+Decitabine+Zantrene (or w/ panobinostat/olaparib), given the work Borje has published? Waiting two years for Decitibine+Zan interim results to then decide to proceed with Zan+SoC... seems like we'd be delaying the possibility of commercial launch in AML and furthering dilution?
https://www.tandfonline.com/doi/full/10.1080/10428194.2022.2042689
Ann: RAC Investor Presentation May 2024, page-12
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |